Video

ASCO 2012: Radium-223 and Prostate Cancer Survival

Publish date: August 20, 2012

 

Dr. Chris Parker of Royal Marsden Hospital in London discusses the ALSYMPCA trial of radium-223 (Alpharadin), the first agent to improve prostate cancer survival by targeting bone metastases.

Recommended Reading

Assessing Prostate Cancer Risk: Can Genomics Help?
MDedge Hematology and Oncology
Depression May Shorten Survival in Kidney Cancer
MDedge Hematology and Oncology
Prostate Cancer Insights From ASCO 2012
MDedge Hematology and Oncology
ASCO 2012: Radiotherapy for Locally Advanced Prostate Cancer
MDedge Hematology and Oncology
Romidepsin-Decitabine Duo Battles Breast and Kidney Cancers
MDedge Hematology and Oncology
Enzalutamide Prolongs Prostate Cancer Survival After Chemotherapy Fails
MDedge Hematology and Oncology
Experimental Drug Improves Muscle Strength in Cancer
MDedge Hematology and Oncology
New Analysis Revises Benefits of PSA Screening Downward
MDedge Hematology and Oncology
Blood Test May Predict Temsirolimus Response in Kidney Cancer
MDedge Hematology and Oncology
Abiraterone increases survival in metastatic prostate cancer
MDedge Hematology and Oncology